Vanguard Group Inc T Scan Therapeutics, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,808,152 shares of TCRX stock, worth $15.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,808,152

Previous 1,788,152 1.12%

Holding current value

$15.5 Million

Previous $10.4 Million 37.72%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$4.89 - $8.3 $97,800 - $166,000	20,000 Added 1.12%	1,808,152 $14.4 Million
Q4 2023 Feb 14, 2024	BUY	$2.66 - $6.76 $94,584 - $240,372	35,558 Added 2.03%	1,788,152 $10.4 Million
Q3 2023 Nov 14, 2023	BUY	$2.04 - $2.94 $802,342 - $1.16 Million	393,305 Added 28.93%	1,752,594 $4.49 Million
Q2 2023 Aug 14, 2023	BUY	$1.64 - $4.85 $1.74 Million - $5.15 Million	1,062,464 Added 357.94%	1,359,289 $3.4 Million
Q1 2023 May 15, 2023	BUY	$1.66 - $3.32 $51,079 - $102,159	30,771 Added 11.57%	296,825 $623,000

Q4 2022 Feb 10, 2023	BUY	$1.49 - $2.86 $12,870 - $24,704	8,638 Added 3.36%	266,054 $412,000
Q3 2022 Nov 14, 2022	BUY	$2.62 - $4.39 $82,142 - $137,635	31,352 Added 13.87%	257,416 $785,000
Q2 2022 Aug 12, 2022	SELL	$1.65 - $3.58 $1,427 - $3,096	-865 Reduced 0.38%	226,064 $711,000
Q1 2022 May 13, 2022	SELL	$2.8 - $5.4 $31,037 - $59,859	-11,085 Reduced 4.66%	226,929 $636,000
Q4 2021 Feb 14, 2022	SELL	$4.5 - $9.05 $930,960 - $1.87 Million	-206,880 Reduced 46.5%	238,014 $1.07 Million
Q3 2021 Nov 12, 2021	BUY	$6.17 - $13.48 $2.74 Million - $6 Million	444,894 New	444,894 $3.71 Million

Others Institutions Holding TCRX

# of Institutions

Shares Held

29.3M

Call Options Held

Put Options Held

View Full List

About TScan Therapeutics, Inc.

Ticker TCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,929,800
Market Cap $162M
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...

More about TCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc T Scan Therapeutics, Inc. Transaction History